Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
ClearView Healthcare Partners Makes Strategic Investment in Epistemic AI to Advance Next-Generation Biomedical AI Platform
-
Barrick Recommends Shareholders Reject TRC Capital’s Below-Market “Mini-Tender” Offer for Common Shares
-
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
-
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France
-
Bunker Hill Provides Project and Corporate Update
-
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
-
Aduro Clean Technologies to Ring the Nasdaq Closing Bell on Friday, January 17th, 2025
-
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
-
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
-
Five Below, Inc. Announces Holiday Sales Results for Quarter-To-Date Through January 4, 2025
-
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones
-
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
-
Abercrombie & Fitch Co. Increases Fourth Quarter and Full Year Net Sales Outlook on Better-Than-Expected Holiday Sales
-
Travere Therapeutics Provides Corporate Update and 2025 Outlook
-
Autolus Therapeutics Provides Business Updates and 2025 Overview
-
Destination XL Group, Inc. Reports Holiday Sales Results
-
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
-
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
-
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
-
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
-
iBio Announces New Investments from Board Members and Officers
-
Braves Announce Exclusive Gray Media Spring Training Action
-
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
-
Oatly to Report Fourth Quarter 2024 Financial Results on February 12, 2025
-
Mastercard and FreedomPay Unlock Global Commerce With New Payment Gateway Partnership
-
Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer
-
EDAP Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures
-
ClearView Healthcare Partners Makes Strategic Investment in Epistemic AI to Advance Next-Generation Biomedical AI Platform
-
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America
-
Schouw & Co. share buy-back programme, week 2 2025
-
Avacta Appoints Brian Hahn as Chief Financial Officer
-
Devon Energy Announces Updates to Executive Leadership Team
-
Alamos Gold Continues to Define High-Grade Mineralization Across the Island Gold Deposit; Ongoing Success Expected to Drive Additional Growth in Mineral Reserves and Resources
-
Pharvaris Outlines 2025 Strategic Priorities
-
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook
-
Goliath Drills Remarkable Hole Assaying 34.52 g/t AuEq (1.11 oz/T AuEq) Over 39.00 Meters, Including 132.93 g/t AuEq (4.27 oz/T AuEq) Over 10.00 Meters, Plus Several High-Grade Holes With Multiple Int
-
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
-
Brazil Potash Subsidiary Potássio do Brasil, Signs Preliminary Agreement with Mura Indigenous People for Autazes Potash Project
-
Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2024 and Provides Initial 2025 Revenue Guidance
-
AirSculpt Technologies Updates Fiscal Year 2024 Guidance in Advance of its Participation in the ICR Conference 2025
-
Fincover®.com Launches Revolutionary Fintech Marketplace for Financial Services
-
Nomad Internet Announced the Unlimited Power Plan, Offering High-Speed Internet, Unlimited Data, and a Free Modem
-
Form 8.5 (EPT/RI) - Brand Architekts Group plc
-
PACS FINAL DEADLINE ALERT: PACS Group (PACS) Investors Alerted to Today’s Lead Plaintiff Deadline in Securities Class Action
-
Dimensional Fund Advisors Ltd. : Form 8.3 - INTERNATIONAL PAPER CO - Ordinary Shares
-
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
-
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
-
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
-
Comstock Releases Shareholder Letter
-
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
